Cardiogenic Shock Complicating Myocardial Infarction: An Updated Review

References (192)

1. 1 An International Randomized Trial Comparing Four Thrombolytic Strategies for Acute Myocardial Infarction [DOI]
2. 2 The effectiveness of right heart catheterization in the initial care of critically ill patients. SUPPORT Investigators [DOI]
3. 3 Cardiogenic shock complicating acute myocardial infarction—etiologies, management and outcome: a report from the SHOCK Trial Registry [DOI]
4. 4 Trends in Management and Outcomes of Patients With Acute Myocardial Infarction Complicated by Cardiogenic Shock [DOI]
5. 5 Percutaneous left ventricular assist devices vs. intra-aortic balloon pump counterpulsation for treatment of cardiogenic shock: a meta-analysis of controlled trials [DOI]
6. 6 Current Spectrum of Cardiogenic Shock and Effect of Early Revascularization on Mortality [DOI]
7. 7 Ten-Year Trends in the Incidence and Treatment of Cardiogenic Shock [DOI]
8. 8 A Prospective Feasibility Trial Investigating the Use of the Impella 2.5 System in Patients Undergoing High-Risk Percutaneous Coronary Intervention (The PROTECT I Trial) [DOI]
9. 9 Predictors of in-hospital mortality in 1333 patients with acute myocardial infarction complicated by cardiogenic shock treated with primary percutaneous coronary intervention (PCI) Results of the primary PCI registry of the Arbeitsgemeinschaft Leitende Kardiologische Krankenhausärzte (ALKK) [DOI]
10. 10 Intra-aortic balloon pump counterpulsation (IABP) for myocardial infarction complicated by cardiogenic shock [DOI]
11. 11 Adjunctive mechanical devices to prevent distal embolization in patients undergoing mechanical revascularization for acute myocardial infarction: A meta-analysis of randomized trials [DOI]
12. 12 Mild therapeutic hypothermia in cardiogenic shock syndrome* [DOI]
13. 13 Cardiogenic Shock Due to Myocardial Infarction [DOI]
14. 14 Comparison of Hospital Mortality With Intra-Aortic Balloon Counterpulsation Insertion Before Versus After Primary Percutaneous Coronary Intervention for Cardiogenic Shock Complicating Acute Myocardial Infarction [DOI]
15. 15 Contemporary utilization and outcomes of intra-aortic balloon counterpulsation in acute myocardial infarction [DOI]
16. 16 Use of Intraaortic Balloon Counterpulsation in Patients Presenting With Cardiogenic Shock: Observations From the GUSTO-I Study fn1fn1This study was funded by grants from Bayer, New York, New York; CIBA-Corning, Medfield, Massachusetts; Genentech, South San Francisco, California; ICI Pharmaceuticals, Wilmington, Delaware; and Sanofi Pharmaceuticals, Paris, France. [DOI]
17. 17 Platelet glycoprotein IIb/IIIa blockade and outcome of cardiogenic shock complicating acute coronary syndromes without persistent ST-segment elevation [DOI]
18. 18 Present use of bedside right heart catheterization in patients with cardiac disease11This Expert Consensus Document was approved by the American College of Cardiology Board of Trustees in March 1998.22Address for reprints: Educational Services, American College of Cardiology, 9111 Old Georgetown Road, Bethesda, Maryland 20814-1699. [DOI]
19. 19 Mortality After Emergent Percutaneous Coronary Intervention in Cardiogenic Shock Secondary to Acute Myocardial Infarction and Usefulness of a Mortality Prediction Model [DOI]
20. 20 Use and Outcomes of Multivessel Percutaneous Coronary Intervention in Patients With Acute Myocardial Infarction Complicated by Cardiogenic Shock (from the EHS-PCI Registry) [DOI]
21. 21 Effects of levosimendan versus dobutamine on long-term survival of patients with cardiogenic shock after primary coronary angioplasty [DOI]
22. 22 Post-Myocardial Infarction Cardiogenic Shock Is a Systemic Illness in Need of Systemic Treatment [DOI]
23. 23 Pathophysiology, diagnosis, and treatment of infarction-related cardiogenic shock [DOI]
24. 24 Successful Conversion of TandemHeart Left Ventricular Assist Device to Right Ventricular Assist Device After Implantation of a HeartMate XVE [DOI]
25. 25 Role of a Percutaneous Ventricular Assist Device in Decision Making for a Cardiac Transplant Program [DOI]
26. 26 Role of receptor for advanced glycation end products in cardiogenic shock* [DOI]
27. 27 Hemodynamic Spectrum of Myocardial Infarction and Cardiogenic Shock [DOI]
28. 28 Systematic Direct Angioplasty and Stent-Supported Direct Angioplasty Therapy for Cardiogenic Shock Complicating Acute Myocardial Infarction: In-Hospital and Long-Term Survival [DOI]
29. 29 L-NMMA (a Nitric Oxide Synthase Inhibitor) is Effective in the Treatment of Cardiogenic Shock [DOI]
30. 30 The German multicenter trial of anisoylated plasminogen streptokinase activator complex versus heparin for acute myocardial infarction [DOI]
31. 31 SHOCK SYNDROME PRODUCED BY FAILURE OF THE HEART [DOI]
32. 32 Percutaneous left ventricular assist devices for treatment of patients with cardiogenic shock [DOI]
33. 33 Effects of levosimendan versus dobutamine on left ventricular diastolic function in patients with cardiogenic shock after primary angioplasty [DOI]
34. 34 The Tragedy of TRIUMPH for Nitric Oxide Synthesis Inhibition in Cardiogenic Shock [DOI]
35. 35 Outcome of emergency conventional coronary surgery for acute coronary syndrome due to left main coronary disease.
36. 36 Percutaneous coronary intervention for unprotected left main disease in very high risk patients: safety of drug-eluting stents [DOI]
37. 37 A prospective, randomized trial of continuous lateral rotation (“kinetic therapy”) in patients with cardiogenic shock [DOI]
38. 38 The role of Ca++-sensitizers for the treatment of heart failure [DOI]
39. 39 Cardiogenic shock: Basics and clinical considerations [DOI]
40. 40 Impact of stents and abciximab on survival from cardiogenic shock treated with percutaneous coronary intervention [DOI]
41. 41 Comparison of Invasive and Non-Invasive Treatment Strategies in Older Patients With Acute Myocardial Infarction Complicated by Cardiogenic Shock (from the Polish Registry of Acute Coronary Syndromes - PL-ACS) [DOI]
42. 42 Marked systemic hypotension depresses coronary thrombolysis induced by intracoronary administration of recombinant tissue-type plasminogen activator [DOI]
43. 43 Outcomes According to Presentation With Versus Without Cardiogenic Shock in Patients With Left Main Coronary Artery Stenosis and Acute Myocardial Infarction [DOI]
44. 44 Ischaemic cardiogenic shock [DOI]
45. 45 Studies in clinical shock and hypotension [DOI]
46. 46 Treatment of cardiogenic shock in myocardial infarction by intraaortic balloon counterpulsation and surgery [DOI]
47. 47 New pharmacologic approaches for the perioperative treatment of ischemic cardiogenic shock [DOI]
48. 48 Cardiogenic Shock: A Historical Perspective [DOI]
49. 49 Percutaneous Ventricular Assist Devices: NewDeus Ex Machina? [DOI]
50. 50 Outcomes with pulmonary artery catheterization in cardiogenic shock [DOI]
51. 51 Early Revascularization in Acute Myocardial Infarction Complicated by Cardiogenic Shock [DOI]
52. 52 Guidelines on myocardial revascularization [DOI]
53. 53 CLINICAL FEATURES OF SUDDEN OBSTRUCTION OF THE CORONARY ARTERIES [DOI]
54. 54 Initial Clinical Experience With Intraaortic Balloon Pumping in Cardiogenic Shock [DOI]
55. 55 Intra-Aortic Balloon Counterpulsation in Cardiogenic Shock [DOI]
56. 56 Cardiac Release of Cytokines and Inflammatory Responses in Acute Myocardial Infarction [DOI]
57. 57 The Percutaneous Ventricular Assist Device in Severe Refractory Cardiogenic Shock [DOI]
58. 58 Effects of a new calcium sensitizer, levosimendan, on haemodynamics, coronary blood flow and myocardial substrate utilization early after coronary artery bypass grafting [DOI]
59. 59 Levosimendan is superior to enoximone in refractory cardiogenic shock complicating acute myocardial infarction* [DOI]
60. 60 Thrombolysis and Counterpulsation to Improve Survival in Myocardial Infarction Complicated by Hypotension and Suspected Cardiogenic Shock or Heart Failure: Results of the TACTICS Trial [DOI]
61. 61 Implications of the timing of onset of cardiogenic shock after acute myocardial infarction: a report from the SHOCK Trial Registry [DOI]
62. 62 Correlates of one-year survival inpatients with cardiogenic shock complicating acute myocardial infarction [DOI]
63. 63 Do All Nonsurvivors of Cardiogenic Shock Die With a Low Cardiac Index? * [DOI]
64. 64 Efficacy of veno-arterial extracorporeal membrane oxygenation in acute myocardial infarction with cardiogenic shock [DOI]
65. 65 Diastolic balloon pumping (with carbon dioxide) in the aorta—A mechanical assistance to the failing circulation [DOI]
66. 66 Pharmacology and Biological Efficacy of a Recombinant, Humanized, Single-Chain Antibody C5 Complement Inhibitor in Patients Undergoing Coronary Artery Bypass Graft Surgery With Cardiopulmonary Bypass [DOI]
67. 67 Thrombolysis Plus Aortic Counterpulsation: Improved Survival in Patients Who Present to Community Hospitals With Cardiogenic Shock [DOI]
68. 68 Predictors of cardiogenic shock after thrombolytic therapy for acute myocardial infarction [DOI]
69. 69 Predictors of in-hospital mortality after percutaneous coronary intervention for cardiogenic shock [DOI]
70. 70 Predictors of 30-day mortality in patients with refractory cardiogenic shock following acute myocardial infarction despite a patent infarct artery [DOI]
71. 71 Cytokines and Myocardial Dysfunction: State of the Art [DOI]
72. 72 Comparative outcomes in cardiogenic shock patients managed with Impella microaxial pump or extracorporeal life support [DOI]
73. 73 Percutaneous coronary intervention or coronary artery bypass surgery for cardiogenic shock and multivessel coronary artery disease? [DOI]
74. 74 Comparison of impact of primary percutaneous transluminal coronary angioplasty and primary stenting on short-term mortality in patients with cardiogenic shock and evaluation of prognostic determinants [DOI]
75. 75 Survival of Elderly Patients Undergoing Percutaneous Coronary Intervention for Acute Myocardial Infarction Complicated by Cardiogenic Shock [DOI]
76. 76 The Use of Vasopressors and Inotropes in the Emergency Medical Treatment of Shock [DOI]
77. 77 Percutaneous Left Ventricular Support Devices [DOI]
78. 78 Early revascularization is beneficial across all ages and a wide spectrum of cardiogenic shock severity: A pooled analysis of trials [DOI]
79. 79 The role of cAMP- and cGMP-dependent protein kinases in the cardiac actions of the new calcium sensitizer, levosimendan [DOI]
80. 80 Effect of nitric oxide synthase inhibition on haemodynamics and outcome of patients with persistent cardiogenic shock complicating acute myocardial infarction: a phase II dose-ranging study [DOI]
81. 81 Abciximab therapy improves survival in patients with acute myocardial infarction complicated by early cardiogenic shock undergoing coronary artery stent implantation [DOI]
82. 82 Percutaneous cardiopulmonary bypass for cardiac emergencies [DOI]
83. 83 Clinical perspectives and therapeutics of thrombolysis [DOI]
84. 84 The use of extracorporeal membrane oxygenation in patients with therapy refractory cardiogenic shock as a bridge to implantable left ventricular assist device and perioperative right heart support [DOI]
85. 85 Mortality of patients with ST-segment elevation myocardial infarction and cardiogenic shock treated by PCI is correlated to the infarct-related artery – Results from the PL-ACS Registry [DOI]
86. 86 Dobutamine-norepinephrine, but not vasopressin, restores the ventriculoarterial matching in experimental cardiogenic shock [DOI]
87. 87 Percutaneous coronary intervention with stenting of left main coronary artery with drug-eluting stent in the setting of acute ST elevation myocardial infarction [DOI]
88. 88 Percutaneous left ventricular support for high-risk PCI and cardiogenic shock: who gets what? [DOI]
89. 89 Routine percutaneous coronary intervention in elderly patients with cardiogenic shock complicating acute myocardial infarction [DOI]
90. 90 Assist devices for circulatory support in therapy-refractory acute heart failure [DOI]
91. 91 Thrombus aspiration during primary angioplasty for cardiogenic shock [DOI]
92. 92 Results of primary percutaneous transluminal coronary angioplasty plus abciximab with or without stenting for acute myocardial infarction complicated by cardiogenic shock [DOI]
93. 93 Cardiogenic Shock Complicating Myocardial Infarction [DOI]
94. 94 Evaluation of therapy in shock following acute myocardial infarction [DOI]
95. 95 The Role of Angiography in Cardiogenic Shock [DOI]
96. 96 Reflections on early stopping of a clinical trial [DOI]
97. 97 Cardiogenic Shock: Treatment [DOI]
98. 98 Cardiogenic shock in acute coronary syndromes—miles to go? [DOI]
99. 99 Clinical implications of cytokines in the critical-care unit [DOI]
100. 100 Use of inotropes in the critical care setting [DOI]
101. 101 Intraaortic Balloon Support for Myocardial Infarction with Cardiogenic Shock [DOI]
102. 102 Management of acute myocardial infarction in patients presenting with persistent ST-segment elevation [DOI]
103. 103 Comparison of Dopamine and Norepinephrine in the Treatment of Shock [DOI]
104. 104 A Randomized Clinical Trial to Evaluate the Safety and Efficacy of a Percutaneous Left Ventricular Assist Device Versus Intra-Aortic Balloon Pumping for Treatment of Cardiogenic Shock Caused by Myocardial Infarction [DOI]
105. 105 Thrombus Aspiration during Primary Percutaneous Coronary Intervention [DOI]
106. 106 One-Year Survival Following Early Revascularization for Cardiogenic Shock [DOI]
107. 107 Thirty-Year Trends (1975 to 2005) in the Magnitude of, Management of, and Hospital Death Rates Associated With Cardiogenic Shock in Patients With Acute Myocardial Infarction [DOI]
108. 108 Abciximab as Adjunctive Therapy to Reperfusion in Acute ST-Segment Elevation Myocardial Infarction [DOI]
109. 109 Safety and efficacy of a novel calcium sensitizer, levosimendan, in patients with left ventricular failure due to an acute myocardial infarction. A randomized, placebo-controlled, double-blind study (RUSSLAN) [DOI]
110. 110 A randomized multicenter clinical study to evaluate the safety and efficacy of the TandemHeart percutaneous ventricular assist device versus conventional therapy with intraaortic balloon pumping for treatment of cardiogenic shock [DOI]
111. 111 Inhibition of the Sodium-Hydrogen Exchanger With Cariporide to Prevent Myocardial Infarction in High-Risk Ischemic Situations [DOI]
112. 112 Contemporary reperfusion therapy for cardiogenic shock: The GUSTO-I trial experience [DOI]
113. 113 Intra-aortic balloon counterpulsation in patients with acute myocardial infarction complicated by cardiogenic shock: The prospective, randomized IABP SHOCK Trial for attenuation of multiorgan dysfunction syndrome* [DOI]
114. 114 The Na+/H+exchange inhibitor eniporide as an adjunct to early reperfusion therapy for acute myocardial infarction11This manuscript is dedicated to the memory of Karl-Ludwig Neuhaus (1944–2000). [DOI]
115. 115 Pexelizumab, an Anti-C5 Complement Antibody, as Adjunctive Therapy to Primary Percutaneous Coronary Intervention in Acute Myocardial Infarction [DOI]
116. 116 Impact of thrombolysis, intra-aortic balloon pump counterpulsation, and their combination in cardiogenic shock complicating acute myocardial infarction: a report from the SHOCK Trial Registry [DOI]
117. 117 The use of intra-aortic balloon counterpulsation in patients with cardiogenic shock complicating acute myocardial infarction: Data from the National Registry of Myocardial Infarction 2 [DOI]
118. 118 Early revascularization is associated with improved survival in elderly patients with acute myocardial infarction complicated by cardiogenic shock: a report from the SHOCK Trial Registry [DOI]
119. 119 Comparison of Percutaneous Coronary Intervention and Coronary Artery Bypass Grafting After Acute Myocardial Infarction Complicated by Cardiogenic Shock [DOI]
120. 120 A severity scoring system for risk assessment of patients with cardiogenic shock: A report from the SHOCK Trial and Registry [DOI]
121. 121 Extracorporeal membrane oxygenation–assisted primary percutaneous coronary intervention may improve survival of patients with acute myocardial infarction complicated by profound cardiogenic shock [DOI]
122. 122 Relation Between Hospital Intra-Aortic Balloon Counterpulsation Volume and Mortality in Acute Myocardial Infarction Complicated by Cardiogenic Shock [DOI]
123. 123 The Impella 2.5 and 5.0 devices for ST-elevation myocardial infarction patients presenting with severe and profound cardiogenic shock: The Academic Medical Center intensive care unit experience* [DOI]
124. 124 Cardiogenic shock complicating acute coronary syndromes: Insights from the Global Registry of Acute Coronary Events [DOI]
125. 125 Effect of Multivessel Coronary Disease With or Without Concurrent Chronic Total Occlusion on One-Year Mortality in Patients Treated With Primary Percutaneous Coronary Intervention for Cardiogenic Shock [DOI]
126. 126 Moderate hypothermia for severe cardiogenic shock (COOL Shock Study I & II) [DOI]
127. 127 Meta-Analysis of Clinical Studies Comparing Coronary Artery Bypass Grafting With Percutaneous Coronary Intervention and Drug-Eluting Stents in Patients With Unprotected Left Main Coronary Artery Narrowings [DOI]
128. 128 A randomized evaluation of early revascularization to treat shock complicating acute myocardial infarction. The (Swiss) Multicenter Trial of Angioplasty for Shock—(S)MASH [DOI]
129. 129 Percutaneous coronary intervention for cardiogenic shock in the SHOCK Trial Registry [DOI]
130. 130 Outcome Evaluation of the Bridge to Bridge Concept in Patients With Cardiogenic Shock [DOI]
131. 131 A Decade of Short-Term Outcomes in Post–Cardiac Surgery Ventricular Assist Device Implantation [DOI]
132. 132 Effect of Vasopressin on Hemodynamics in Patients With Refractory Cardiogenic Shock Complicating Acute Myocardial Infarction [DOI]
133. 133 Hand-held minimised extracorporeal membrane oxygenation: a new bridge to recovery in patients with out-of-centre cardiogenic shock☆☆☆ [DOI]
134. 134 Meta‐analysis of randomized trials comparing anti‐embolic devices with standard PCI for improving myocardial reperfusion in patients with acute myocardial infarction [DOI]
135. 135 Veno-arterial extracorporeal membrane oxygenation using Levitronix centrifugal pump as bridge to decision for refractory cardiogenic shock [DOI]
136. 136 Clinical and Hemodynamic Results of Intraaortic Balloon Pumping and Surgery for Cardiogenic Shock [DOI]
137. 137 Intraaortic balloon counterpulsation with and without reperfusion for myocardial infarction shock. [DOI]
138. 138 Acute myocardial infarction treated with intracoronary streptokinase: A report of the society for cardiac angiography [DOI]
139. 139 Long-term mortality benefit with the combination of stents and abciximab for cardiogenic shock complicating acute myocardial infarction [DOI]
140. 140 Involvement of inducible nitric oxide synthase in the inflammatory process of myocardial infarction [DOI]
141. 141 Early and late clinical outcomes after primary stenting of the unprotected left main coronary artery stenosis in the setting of acute myocardial infarction [DOI]
142. 142 Temporary Extracorporeal Membrane Oxygenation in Patients with Refractory Postoperative Cardiogenic Shock-A Single Center Experience [DOI]
143. 143 Primary percutaneous coronary intervention for acute myocardial infarction caused by unprotected left main stem thrombosis [DOI]
144. 144 Mechanical Circulatory Support for Cardiogenic Shock Complicating Acute Myocardial Infarction: An Experimental and Clinical Review [DOI]
145. 145 Tolerability of extended duration intravenous milrinone in patients hospitalized for advanced heart failure and the usefulness of uptitration of oral angiotensin-converting enzyme inhibitors [DOI]
146. 146 Levosimendan: a promising treatment for myocardial stunning? [DOI]
147. 147 Do not get in RAGE in cardiogenic shock [DOI]
148. 148 Limitations of thrombolytic therapy for acute myocardial infarction complicated by congestive heart failure and cardiogenic shock [DOI]
149. 149 Utility of Levosimendan, a New Calcium Sensitizing Agent, in the Treatment of Cardiogenic Shock Due to Myocardial Stunning in Patients With ST‐Elevation Myocardial Infarction: A Series of Cases [DOI]
150. 150 Management strategies for cardiogenic shock [DOI]
151. 151 ACC/AHA Guidelines for the Management of Patients With ST-Elevation Myocardial Infarction—Executive Summary [DOI]
152. 152 ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation [DOI]
153. 153 Intensive versus Conventional Glucose Control in Critically Ill Patients [DOI]
154. 154 2011 ACCF/AHA/SCAI Guideline for Percutaneous Coronary Intervention [DOI]
155. 155 Guidelines on myocardial revascularization [DOI]
156. 156 The Effectiveness of Right Heart Catheterization in the Initial Care of Critically III Patients [DOI]
157. 157 2009 Focused Updates: ACC/AHA Guidelines for the Management of Patients With ST-Elevation Myocardial Infarction (Updating the 2004 Guideline and 2007 Focused Update) and ACC/AHA/SCAI Guidelines on Percutaneous Coronary Intervention (Updating the 2005 Guideline and 2007 Focused Update) [DOI]
158. 158 2009 Focused Updates: ACC/AHA Guidelines for the Management of Patients With ST-Elevation Myocardial Infarction (Updating the 2004 Guideline and 2007 Focused Update) and ACC/AHA/SCAI Guidelines on Percutaneous Coronary Intervention (Updating the 2005 Guideline and 2007 Focused Update) [DOI]
159. 159 Treatment of myocardial infarction in a coronary care unit.
160. 160 Decline in Rates of Death and Heart Failure in Acute Coronary Syndromes, 1999-2006 [DOI]
161. 161 Cardiogenic Shock [DOI]
162. 162 Early Revascularization and Long-term Survival in Cardiogenic Shock Complicating Acute Myocardial Infarction [DOI]
163. 163 Randomized comparison of intra-aortic balloon support with a percutaneous left ventricular assist device in patients with revascularized acute myocardial infarction complicated by cardiogenic shock [DOI]
164. 164 Cardiogenic Shock Complicating Acute Myocardial Infarction [DOI]
165. 165 A systematic review and meta-analysis of intra-aortic balloon pump therapy in ST-elevation myocardial infarction: should we change the guidelines? [DOI]
166. 166 Medical Therapy of Acute Myocardial Infarction by Application of Hemodynamic Subsets [DOI]
167. 167 Emergency circulatory support in refractory cardiogenic shock patients in remote institutions: a pilot study (the cardiac-RESCUE program) [DOI]
168. 168 Cardiogenic Shock in Patients With Acute Ischemic Syndromes With and Without ST-Segment Elevation [DOI]
169. 169 Improved outcome of cardiogenic shock at the acute stage of myocardial infarction: a report from the USIK 1995, USIC 2000, and FAST-MI French Nationwide Registries [DOI]
170. 170 Quantitative troponin and death, cardiogenic shock, cardiac arrest and new heart failure in patients with non-ST-segment elevation acute coronary syndromes (NSTE ACS): insights from the Global Registry of Acute Coronary Events [DOI]
171. 171 Percutaneous Circulatory Support in Cardiogenic Shock [DOI]
172. 172 Cardiovascular Outcomes Using Intra-Aortic Balloon Pump in High-Risk Acute Myocardial Infarction With or Without Cardiogenic Shock [DOI]
173. 173 Myocardial Changes Associated with Cardiogenic Shock [DOI]
174. 174 LINCS: L-NAME (a NO synthase inhibitor) In the treatment of refractory Cardiogenic Shock A prospective randomized study [DOI]
175. 175 Cardiogenic shock complicating acute myocardial infarction Prognostic impact of early and late shock development [DOI]
176. 176 Percutaneous left ventricular assist devices in acute myocardial infarction complicated by cardiogenic shock [DOI]
177. 177 First experience with the ultra compact mobile extracorporeal membrane oxygenation system Cardiohelp in interhospital transport [DOI]
178. 178 The history of coronary care units. [DOI]
179. 179 Current status of percutaneous ventricular assist devices for cardiogenic shock [DOI]
180. 180 Percutaneous Endocardial and Epicardial Ablation of Hypotensive Ventricular Tachycardia with Percutaneous Left Ventricular Assist in the Electrophysiology Laboratory [DOI]
181. 181 Use of a percutaneous left ventricular assist device for high-risk cardiac interventions and cardiogenic shock.
182. 182 In-hospital mortality and clinical course of 20 891 patients with suspected acute myocardial infarction randomised between alteplase and streptokinase with or without heparin [DOI]
183. 183 The Treatment of Shock Associated with Myocardial Infarction [DOI]
184. 184 Emergency revascularization in patients with cardiogenic shock on admission: a report from the SHOCK trial and registry [DOI]
185. 185 Cardiogenic Shock After Primary Percutaneous Coronary Intervention: Effects of Levosimendan Compared with Dobutamine on Haemodynamics [DOI]
186. 186 RUSSLAN STUDY INVESTIGATORS. SAFETY AND EFFICACY OF A NOVEL CALCIUM SENSITIZER, LEVOSIMENDAN, IN PATIENTS WITH LEFT VENTRICULAR FAILURE DUE TO AN ACUTE MYOCARDIAL INFARCTION. A RANDOMIZED, PLACEBO-CONTROLLED, DOUBLE-BLIND STUDY (RUSSLAN)
187. 187 Predictors of outcome after percutaneous treatment for cardiogenic shock [DOI]
188. 188 Levosimendan: a new era for inodilator therapy for heart failure? [DOI]
189. 189 Emergency Percutaneous Coronary Intervention in Unprotected Left Main Coronary Arteries. Predictors of Mortality and Impact of Cardiogenic Shock [DOI]
190. 190 Intracoronary infusion of dobutamine to patients with and without severe congestive heart failure. Dose-response relationships, correlation with circulating catecholamines, and effect of phosphodiesterase inhibition. [DOI]
191. 191 Cardiogenic shock: role of revascularization.
192. 192 Outcome of patients after coronary artery bypass grafting in cardiogenic shock.

Cited by 5

Showing 3 of 5 known citations — external sources report more than can currently be individually listed.

Related research

• Satisfaction with Quality of Health Care among Teaching Hospitals in Kathmandu, Nepal — shares topic coverage
• Etiology and Management of Epistaxis in Makurdi, North-Central Nigeria: An Eight Year Descriptive Review — shares topic coverage
• The Hospital: A Complex Adaptive System — shares topic coverage
• Overview of Causes, Risk Factors and Management of Sciatica: A Review — shares topic coverage
• Updates in Diagnosis and Management of Melasma : A Simple Review Article — shares topic coverage